

November 28, 2019

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Product Registration in Turkmenistan

Ref.: Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that we, Zota Health Care Limited (the "Company") have received product registration licenses for below mentioned three products from Turkmenistan.

Sr. No.	Name of Product	Therapeutic Category
1	CDTEL-H (Tablet – Each tablet contains Telmisartan 40 MG + Hydrochlorothiazide 12.5 MG)	Angiotensin receptor blocker
2	MONTIZED – L (Tablet – Each tablet contains Levocetirizine 5 mg + Montelukast 10 mg)	leukotriene receptor antagonists
3	TAMZED -0.4 (Capsule – Each hard gelatin capsule contains Tamsulosin Hydrochloride {as sustained release pellets} 0.4mg.)	Alpha Blocker

We have received licenses for the aforementioned products for the validity period of five years, licenses for the products are also renewable. Company shall start exporting these products in Turkmenistan very soon.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited



Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat



Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122